Martine M Bellanger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3301968/publications.pdf

Version: 2024-02-01

567281 434195 1,099 31 15 31 citations h-index g-index papers 33 33 33 1757 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Estimating Burden and Disease Costs of Exposure to Endocrine-Disrupting Chemicals in the European Union. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1245-1255.	3.6	270
2	Neurobehavioral Deficits, Diseases, and Associated Costs of Exposure to Endocrine-Disrupting Chemicals in the European Union. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1256-1266.	3.6	133
3	Economic benefits of methylmercury exposure control in Europe: Monetary value of neurotoxicity prevention. Environmental Health, 2013, 12, 3.	4.0	123
4	Calculation of the disease burden associated with environmental chemical exposures: application of toxicological information in health economic estimation. Environmental Health, 2017, 16, 123.	4.0	67
5	Are Global Breast Cancer Incidence and Mortality Patterns Related to Country-Specific Economic Development and Prevention Strategies?. Journal of Global Oncology, 2018, 4, 1-16.	0.5	62
6	Childhood lead exposure in France: benefit estimation and partial cost-benefit analysis of lead hazard control. Environmental Health, 2011, 10, 44.	4.0	56
7	Projecting Long-term Health and Economic Burden of COPD in the UnitedÂStates. Chest, 2021, 159, 1400-1410.	0.8	55
8	The "Health Benefit Basket―in France. European Journal of Health Economics, 2005, 6, 24-29.	2.8	49
9	The search for the Holy Grail: combining decentralised planning and contracting mechanisms in the French health care system. Health Economics (United Kingdom), 2005, 14, S119-S132.	1.7	34
10	Accounting and reimbursement schemes for inpatient care in France. Health Care Management Science, 2006, 9, 295-305.	2.6	34
11	Calculation of Mercury's Effects on Neurodevelopment. Environmental Health Perspectives, 2012, 120, A452; author reply A452.	6.0	30
12	Economic evaluation of health consequences of prenatal methylmercury exposure in France. Environmental Health, 2012, 11, 53.	4.0	22
13	What can we learn from a cross-country comparison of the costs of child delivery?. Health Economics (United Kingdom), 2008, 17, S47-S57.	1.7	20
14	Willingness to pay for informal care in France: the value of funding support interventions for caregivers. Health Economics Review, 2014, 4, 34.	2.0	17
15	The cost-effectiveness of PHQ screening and collaborative care for depression in New York City. PLoS ONE, 2017, 12, e0184210.	2.5	17
16	Implementing hospital pay-for-performance: Lessons learned from the French pilot program. Health Policy, 2017, 121, 407-417.	3.0	16
17	Cost-Effectiveness of Lifestyle-Related Interventions for the Primary Prevention of Breast Cancer: A Rapid Review. Frontiers in Medicine, 2019, 6, 325.	2.6	15
18	Economic inequality caused by feedbacks between poverty and the dynamics of a rare tropical disease: the case of Buruli ulcer in sub-Saharan Africa. Proceedings of the Royal Society B: Biological Sciences, 2015, 282, 20151426.	2.6	13

#	Article	IF	CITATIONS
19	Tackling Regional Health Inequalities in France by Resource Allocation. Applied Health Economics and Health Policy, 2004, 3, 243-250.	2.1	12
20	Cost-Effectiveness of Capping Freeways for Use as Parks: The New York Cross-Bronx Expressway Case Study. American Journal of Public Health, 2018, 108, 379-384.	2.7	10
21	Childbirth and Diagnosis Related Groups (DRGs): patient classification and hospital reimbursement in 11 European countries. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 168, 12-19.	1.1	9
22	Does community-based health insurance improve access to care in sub-Saharan Africa? A rapid review. Health Policy and Planning, 2021, 36, 572-584.	2.7	7
23	Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patients—First Results from the PAPESCO-19 Cohort Study. Cancers, 2021, 13, 3389.	3.7	5
24	Effects of fertility on breast cancer incidence trends: comparing France and US. Cancer Causes and Control, 2021, 32, 903-910.	1.8	4
25	First Evaluation Switching From Ropivacaine to Highly Concentrated Bupivacaine in Intrathecal Mixtures for Cancer Pain. Neuromodulation, 2021, 24, 1215-1222.	0.8	4
26	Health and economic consequences of applying the United States' PM2.5 automobile emission standards to other nations: a case study of France and Italy. Public Health, 2020, 183, 81-87.	2.9	4
27	COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19). Clinical Medicine Insights: Oncology, 2022, 16, 117955492210901.	1.3	3
28	Determinants of the benefits of a short-term personalized intermittent work exercise program (IWEP) among seniors: Results from the CAPS program. European Geriatric Medicine, 2016, 7, 333-339.	2.8	2
29	Comparison of methods for calculating the health costs of endocrine disrupters: a case study on triclosan. Environmental Health, 2017, 16, 55.	4.0	2
30	Editorial: Perspectives in Primary Prevention Research for Breast Cancer: A Focus on Geneâ€"Environment Interactions. Frontiers in Medicine, 2020, 7, 621959.	2.6	2
31	Response to the Letter by Middlebeek and Veuger. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L54-L55.	3.6	2